Express Scripts to cover Mylan’s EpiPen, exclude rivals
NEW YORK (Reuters) – Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc’s versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.
The nation’s largest pharmacy benefit manager said it was excluding alternatives to the auto-injector made by Impax Laboratories Inc, privately held Kaleo and A-S Medication from its widely used list of covered drugs.
Express Scripts has been excluding certain medicines from its coverage list or formulary since 2014, citing concern about costs to its health insurers and corporate customers.
By excluding drugs from its coverage list, Express Scripts said it has been better able to negotiate lower prices from drugmakers, and will save customers an estimated $2.5 billion in 2018, up from $1.8 billion this year.
Mylan faced severe criticism and congressional and legal investigations after it doubled the cost of a pair of EpiPens to around $600 last year, enraging consumers and putting it in the center of the ongoing debate over the high cost of prescription medicines in the United States. It has since offered its own generic version for about $300 in response to the furor.
Mylan could not immediately be reached for comment on Monday.
Express Scripts added 64 new drugs – including the EpiPen alternatives – to its list of drugs that are excluded from insurance coverage for 2018. The list determines whether millions of people with private insurance can easily use an insurance co-pay to buy medicine.
Another important drug excluded from the company’s coverage this year is Neupogen, an Amgen Inc treatment used to boost infection-fighting white blood cells during chemotherapy.
Express Scripts said its “preferred alternatives” to Neupogen were biosimilars Granix and Zarxio, made by Teva Pharmaceutical Industries Ltd and Novartis AG, respectively.
Reporting by Michael Erman; Editing by Matthew Lewis